143 related articles for article (PubMed ID: 35676852)
21. A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV.
Zhang H; Hindman JT; Lin L; Davis M; Shang J; Xiao D; Avihingsanon A; Arora P; Palaparthy R; Girish S; Marathe DD
AIDS; 2024 Jan; 38(1):F1-F9. PubMed ID: 37939141
[TBL] [Abstract][Full Text] [Related]
22. Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study.
Chang HM; Chou PY; Chou CH; Tsai HC
Infect Drug Resist; 2021; 14():4877-4886. PubMed ID: 34853517
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
[TBL] [Abstract][Full Text] [Related]
24. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain.
Torralba M; Rodríguez G; González Gasca FJ; Cuadra F; Barberá J; Geijo P; Silva A; García MI; Ostaiza MA; García Pérez AM; Arroyo E; Larrubia JR; Gutiérrez A; Porras ML; Calvo Sánchez H; Peña-Asensio J; Arias JG; Mendoza I
Ann Pharmacother; 2024 Feb; 58(2):140-147. PubMed ID: 37131300
[TBL] [Abstract][Full Text] [Related]
25. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
26. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
27. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
28. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
Andreatta K; Kulkarni R; Abram ME; Nguyen T; Cao H; Miller MD; White KL
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):519-26. PubMed ID: 25559592
[TBL] [Abstract][Full Text] [Related]
29. Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.
Lazzaro A; Bianchini D; Gentilini Cacciola E; Mezzaroma I; Falciano M; Andreoni C; Fimiani C; Santinelli L; Maddaloni L; Bugani G; Ceccarelli G; Mastroianni CM; d'Ettorre G
Viruses; 2023 May; 15(6):. PubMed ID: 37376522
[TBL] [Abstract][Full Text] [Related]
30. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF.
Mills A; Garner W; Pozniak A; Berenguer J; Speck RM; Bender R; Nguyen T
Patient; 2015 Aug; 8(4):359-71. PubMed ID: 26045359
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound.
Chen GJ; Sun HY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Lin KY; Liu WC; Su YC; Hung CC
J Microbiol Immunol Infect; 2023 Oct; 56(5):988-995. PubMed ID: 37574435
[TBL] [Abstract][Full Text] [Related]
32. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
[TBL] [Abstract][Full Text] [Related]
33. Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study.
Hocqueloux L; Lefeuvre S; Bois J; Brucato S; Alix A; Valentin C; Peyro-Saint-Paul L; Got L; Fournel F; Dargere S; Prazuck T; Fournier A; Gregoire N; McNicholl I; Parienti JJ
J Antimicrob Chemother; 2022 Dec; 78(1):161-168. PubMed ID: 36322475
[TBL] [Abstract][Full Text] [Related]
34. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
[TBL] [Abstract][Full Text] [Related]
35. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Tsai MS; Sun HY; Chen CP; Lee CH; Lee CY; Liu CE; Tang HJ; Hung TC; Li CW; Lee YT; Liou BH; Yang CJ; Hung CC;
Int J Infect Dis; 2023 Jan; 126():39-47. PubMed ID: 36384186
[TBL] [Abstract][Full Text] [Related]
36. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
37. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486
[TBL] [Abstract][Full Text] [Related]
38. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
Squillace N; Ricci E; Maggi P; Taramasso L; Menzaghi B; De Socio GV; Piconi S; Maurizio Celesia B; Orofino G; Sarchi E; Pellicanò GF; Simeone F; Valsecchi L; Bandera A; Cenderello G; Attala L; Angioni G; Falasca K; Cascio A; Bargiacchi O; Di Biagio A; Bonfanti P;
PLoS One; 2023; 18(8):e0289132. PubMed ID: 37556481
[TBL] [Abstract][Full Text] [Related]
39. Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis.
Mazzitelli M; Trunfio M; Putaggio C; Sasset L; Leoni D; Lo Menzo S; Mengato D; Cattelan AM
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009370
[TBL] [Abstract][Full Text] [Related]
40. Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
Hsu RK; Brunet L; Fusco JS; Mounzer K; Lamori JC; Fusco GP
AIDS Res Hum Retroviruses; 2022 Oct; 38(10):782-791. PubMed ID: 35923143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
